PXS-4728 by Syntara for Sleep Disorders: Likelihood of Approval

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

UniSA seeks public support for vital research on deadly brain cancers

The University of South Australia is seeking public support for vital brain cancer research that could potentially save hundreds of lives.

October 31, 2023

Emergent wins $75m BARDA contact for anthrax vaccine

Share this article The current $75m contract option builds on an existing Cyfendus development contract between Emergent and BARDA. Image Credit: Niyazz / Shutterstock. Emergent

November 28, 2023

NICE backs use of hybrid closed loop systems for Type 1 diabetes, if companies offer discounts

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: England’s cost-effectiveness watchdog recommended hybrid

November 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.